- Home
- INCY vs FTAI Comparison
INCY vs FTAI Comparison
Compare INCY & FTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- FTAI
- Stock Information
- Founded
- INCY 1991
- FTAI 2011
- Country
- INCY United States
- FTAI United States
- Employees
- INCY N/A
- FTAI N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- FTAI Misc Corporate Leasing Services
- Sector
- INCY Health Care
- FTAI Industrials
- Exchange
- INCY Nasdaq
- FTAI Nasdaq
- Market Cap
- INCY 17.0B
- FTAI 16.9B
- IPO Year
- INCY 1993
- FTAI 2015
- Fundamental
- Price
- INCY $91.48
- FTAI $181.79
- Analyst Decision
- INCY Buy
- FTAI Strong Buy
- Analyst Count
- INCY 19
- FTAI 12
- Target Price
- INCY $81.73
- FTAI $191.25
- AVG Volume (30 Days)
- INCY 1.7M
- FTAI 817.5K
- Earning Date
- INCY 10-28-2025
- FTAI 10-27-2025
- Dividend Yield
- INCY N/A
- FTAI 0.66%
- EPS Growth
- INCY 900.04
- FTAI N/A
- EPS
- INCY 4.37
- FTAI 4.05
- Revenue
- INCY $4,584,996,000.00
- FTAI $2,142,930,000.00
- Revenue This Year
- INCY $16.41
- FTAI $49.92
- Revenue Next Year
- INCY $10.86
- FTAI $19.07
- P/E Ratio
- INCY $20.90
- FTAI $44.93
- Revenue Growth
- INCY 18.87
- FTAI 55.95
- 52 Week Low
- INCY $53.56
- FTAI $75.06
- 52 Week High
- INCY $92.86
- FTAI $184.44
- Technical
- Relative Strength Index (RSI)
- INCY 67.77
- FTAI 62.73
- Support Level
- INCY $84.38
- FTAI $169.46
- Resistance Level
- INCY $92.86
- FTAI $178.50
- Average True Range (ATR)
- INCY 2.44
- FTAI 6.32
- MACD
- INCY 0.35
- FTAI 0.45
- Stochastic Oscillator
- INCY 86.26
- FTAI 97.21
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About FTAI FTAI Aviation Ltd.
FTAI Aviation Ltd is a aerospace company .It owns and maintains commercial jet engines with a focus on CFM56 engines. FTAI owns and leases jet aircraft which often facilitates the acquisition of engines at attractive prices. It invests in aviation assets and aerospace products that generate stable cash flows with the potential for earnings growth and asset appreciation.